Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
John Dormandy, Bernard H. Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005
Cited by 4,140 works. doi:10.1016/s0140-6736(05)67528-9
Authors
- John Dormandy
- Bernard H. Charbonnel
- D.J.A. Eckland
- Erland Erdmann
- Massimo Massi‐Benedetti
- Ian K. Moules
- Allan M. Skene
- Meng Hee Tan
- Pierre J. Lefèbvre
- Gordon D. Murray
- Eberhard Standl
- Robert G. Wilcox
- Lars Wilhelmsen
- John D. Betteridge
- Kåre I. Birkeland
- Alain Golay
- Robert J. Heine
- Laszlo I Koranyi
- Markku Laakso
- Marian Mokáň
References
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
- Role of Insulin Resistance in Human Disease
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
- Proportional Hazards Tests and Diagnostics Based on Weighted Residuals
- Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
- A desktop guide to Type 2 diabetes mellitus
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
- Thiazolidinediones